دورية أكاديمية
Outcomes and patterns of failure in solitary plasmacytoma: A multicenter rare cancer network study of 258 patients
| العنوان: | Outcomes and patterns of failure in solitary plasmacytoma: A multicenter rare cancer network study of 258 patients |
|---|---|
| المؤلفون: | Ozsahin, M, Tsang, RW, Poortmans, P, Belkacemi, Y, Bolla, M, Dincbas, FO, Landmann, C, Castelain, B, Buijsen, J, Curschmann, J, Kadish, SP, Kowalczyk, A, Anacak, Y, Hammer, J, Nguyen, TD, Studer, G, Cooper, R, Sengoz, M, Scandolaro, L, Zouhair, A |
| المساهمون: | Ege Üniversitesi |
| بيانات النشر: | Elsevier Science Inc |
| سنة النشر: | 2006 |
| المجموعة: | Ege University Institutional Repository |
| مصطلحات موضوعية: | solitary plasmacytoma, multiple myeloma, radiotherapy, prognostic factors |
| الوصف: | 45th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO) -- OCT 19-23, 2003 -- Salt Lake City, UT ; WOS: 000234442200030 ; PubMed ID: 16229966 ; Purpose: To assess the outcomes and patterns of failure in solitary plasmacytoma (SP). Methods and Materials: The data from 258 patients with bone (n = 206) or extramedullary (n = 52) SP without evidence of multiple myeloma (MM) were collected. A histopathologic diagnosis was obtained for all patients. Most (n = 214) of the patients received radiotherapy (RT) alone; 34 received chemotherapy and RT, and 8 surgery alone. The median radiation dose was 40 Gy. The median follow-up was 56 months (range 7-245). Results: The median time to MM development was 21 months (range 2-135), with a 5-year probability of 45%. The 5-year overall survival, disease-free survival, and local control rate was 74%, 50%, and 86%, respectively. On multivariate analyses, the favorable factors were younger age and tumor size < 4 cm for survival; younger age, extramedullary localization, and RT for disease-free survival; and small tumor and RT for local control. Bone localization was the only predictor of MM development. No dose-response relationship was found for doses > 30 Gy, even for larger tumors. Conclusion: Progression to MM remains the main problem. Patients with extramedullary SP had the best outcomes, especially when treated with moderate-dose RT. Chemotherapy and/or novel therapies should be investigated for bone or bulky extramedullary SP. (c) 2006 Elsevier Inc. ; Amer Soc Therapeut Radiol & Oncol (ASTRO) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0360-3016 1879-355X |
| العلاقة: | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; International Journal of Radiation Oncology Biology Physics; https://doi.org/10.1016/j.ijrobp.2005.06.039Test; https://hdl.handle.net/11454/38906Test; 64; 210; 217 |
| DOI: | 10.1016/j.ijrobp.2005.06.039 |
| الإتاحة: | https://doi.org/10.1016/j.ijrobp.2005.06.039Test https://hdl.handle.net/11454/38906Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.9D942787 |
| قاعدة البيانات: | BASE |
| تدمد: | 03603016 1879355X |
|---|---|
| DOI: | 10.1016/j.ijrobp.2005.06.039 |